| Tevimbra (tislelizumab-jsgr) / BeiGene |
ChiCTR2100041934: Effect of neoadjuvant anti-PD-1 monoclonal antibody treatment on perioperative analgesia and POD in patients with non-small cell lung cancer surgery |
|
|
| Recruiting | N/A | 60 | China | Tislelizumab ;placebo | Tianjin Medical University Cancer Institute and Hospital ; Tianjin Medical University Cancer Institute and Hospital, self-raised | nonsmall-cell lung cancer | | | | |
| Completed | N/A | 279 | RoW | Transarterial chemoembolization, TACE, Systemic treatment | Zhejiang University | Hepatocellular Carcinoma | 03/23 | 10/23 | | |
NCT06195254: Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreatic Cancer |
|
|
| Completed | N/A | 19 | RoW | Stereotactic body radiotherapy (SBRT), PD-1 blocking antibody | Peking University Third Hospital | Stereotactic Body Radiotherapy, PD-1 Inhibitors, Pancreatic Cancer | 05/23 | 12/23 | | |
NCT06323382: Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 240 | RoW | Locoregional therapy, TACE/HAIC, Bevacizumab, Atezolizumab, Tislelizumab, Toripalimab, Sintilimab, Camrelizumab | Sun Yat-sen University | Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab | 12/24 | 12/24 | | |
NCT06333561: HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 300 | RoW | Hepatic arterial infusion chemotherapy, Lenvatinib, Tislelizumab, Toripalimab, Sintilimab, Camrelizumab | Sun Yat-sen University | Hepatocellular Carcinoma, Lenvatinib, PD-1 Inhibitor, Hepatic Arterial Infusion Chemotherapy | 12/24 | 12/24 | | |
ChiCTR2000039022: Advanced primary hepatocellular carcinoma treated by radiotherapy combined with tislelizumab: a single arm, single center clinical study |
|
|
| Recruiting | N/A | 50 | China | radiotherapy combined with tislelizumab | Affiliated Hospital of Southwest Medical University ; Affiliated Hospital of Southwest Medical University, Self-raised funds | primary hepatocellular carcinoma | | | | |
NCT04627012: Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma |
|
|
| Completed | N/A | 600 | RoW | Lenvatinib, Opdivo, Camrelizumab, Keytruda, Toripalimab, Sintilimab, Tislelizumab | Sun Yat-sen University, Second Affiliated Hospital of Guangzhou Medical University | Hepatocellular Carcinoma, Anti-PD1 Antibody, Liver Diseases | 12/21 | 07/23 | | |
ChiCTR2000035025: A single-center exploratory randomized controlled study of hyperthermic intraperitoneal chemotherapy combined with PD1 inhibitor in advanced gastric cancer with malignant ascites |
|
|
| Recruiting | N/A | 20 | China | hyperthermic intraperitoneal chemotherapy combined with Tislelizumab ;hyperthermic intraperitoneal chemotherapy combined with palliative chemotherapy | Changzhou No.2 People's Hospital of Jiangsu Province ; Changzhou No.2 People's Hospital of Jiangsu Province, self-raised | Advanced gastric cancer with malignant ascites | | | | |
CCGLC-009, NCT06194695: DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | N/A | 100 | RoW | drug eluting beads-transcatheter arterial chemoembolization, DEB-TACE, envatinib plus anti-PD(L)1 | Ze-yang Ding, MD, Geneplus-Beijing Co. Ltd., Chinese Cooperative Group of Liver Cancer (CCGLC) | Cholangiocarcinoma Non-resectable | 12/24 | 06/25 | | |
ChiCTR2000032509: Efficacy and safety of Tislelizumab plus chemotherapy as first-line treatment in elderly advanced non-small cell lung cancer |
|
|
| Recruiting | N/A | 36 | China | Tislelizumab plus chemotherapy | Jiansu Cancer Hospital ; Jiansu Cancer Hospital, self-financing | Non small cell lung cancer | | | | |
ChiCTR2200055460: Clinical study of drug-loaded microspheres transhepatic arterial chemoembolization combined with PD-1 in the treatment of advanced hepatocellular carcinoma |
|
|
| Recruiting | N/A | 60 | China | D-TACE combined with tislelizumab injection ;D-TACE | Shandong Cancer Hospital ; Shandong Cancer Hospital, Special Fund for Clinical Research | hepatic cancer | | | | |
ChiCTR2100045916: Combination of Teicilizumab and GMOEX for the Second-line Treatment of Postoperative Recurrence of Pancreatic Cancer |
|
|
| Recruiting | N/A | 30 | China | Tislelizumab combined with chemotherapy ;Chemotherapy | Shanghai General Hospital ; Shanghai General Hospital, Drug donation | Pancreatic Cancer | | | | |
ChiCTR2000037488: Chemotherapy combined with Tislelizumab as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: a single-arm pilot study |
|
|
| Not yet recruiting | N/A | 45 | China | Chemotherapy combined with Tislelizumab | Tangdu Hospital, Fourth Military Medical University ; Tangdu Hospital, Fourth Military Medical University, None | esophageal squamous cell carcinoma | | | | |
| Completed | N/A | 826 | RoW | TACE+ICIs, TACE | Zhongda Hospital | Hepatocellular Carcinoma | 05/22 | 02/23 | | |
NCT06011330: Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer |
|
|
| Completed | N/A | 70 | RoW | Fruquintinib combined with anti-PD-1 antibodies, programmed cell death protein 1, immune checkpoint inhibitor | Hunan Cancer Hospital | Colorectal Cancer | 06/22 | 02/23 | | |
NCT04639284: Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC |
|
|
| Recruiting | N/A | 200 | RoW | Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma | 07/22 | 07/23 | | |
NCT06034964: Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC |
|
|
| Active, not recruiting | N/A | 60 | RoW | Tislelizumab, BGB-A317 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Tislelizumab, Chemotherapy, First-line, Gastric Cancer Stage IV | 11/22 | 11/25 | | |
RANT, NCT05277675: Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma ( Study) |
|
|
| Recruiting | N/A | 160 | RoW | Tislelizumab/Sintilimab+Lenvatinib/Bevacizumab, RFA | Southwest Hospital, China | Hepatocellular Carcinoma Recurrent | 11/22 | 10/23 | | |
NCT05027100: Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC |
|
|
| Recruiting | N/A | 33 | RoW | Anlotinib Tislelizumab Irinotecan | Haibo Zhang | Small Cell Lung Cancer (SCLC) | 12/22 | 06/23 | | |
NCT05058755: Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma |
|
|
| Completed | N/A | 62 | RoW | tislelizumab, azacytidine, lenalidomide, Tileilizhu Dankang, tislelizumab, etoposide, pegaspargase | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | 12/22 | 12/23 | | |
NCT05247996: TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma |
|
|
| Not yet recruiting | N/A | 98 | NA | Transcatheter arterial chemoembolization, TACE Thrapy, Multi-target Drug Therapy, Target Therapy, Immunocheckpoint Inhibitor Therapy, Immune Therapy, Systemic Intravenous Chemotherapy, Traditional Chemotherapy | The Central Hospital of Lishui City | Intrahepatic Cholangiocarcinoma | 12/22 | 12/23 | | |
ChiCTR2100046796: Efficacy and safety of arterial infusion chemotherapy (TAI) combined with tirelizumab in the treatment of advanced pancreatic cancer: a prospective study |
|
|
| Recruiting | N/A | 44 | China | arterial infusion chemotherapy (TAI) combined with tirelizumab in the treatment of pancreatic cancer | Cancer Hospital, Chinese Academy of Medical Sciences ; Cancer Hospital, Chinese Academy of Medical Sciences, self-financed | advanced pancreatic cancer | | | | |
ChiCTR2100045124: A Single Arm, Prospective, Multicenter Study to Assess the Safety and Efficacy of Lenvatinib Plus PD-1 Inhibitors (Tislelizumab) as First-line Treatment in Patients with Unresectable Biliary Tract Cancer |
|
|
| Recruiting | N/A | 116 | China | Lenvatinib Plus PD-1 Inhibitors（Tislelizumab） | Sir Run Run Shaw Hospital ; Sir Run Run Shaw Hospital, self-funded | Advanced Biliary Tract Carcinoma | | | | |
ChiCTR2100045296: The clinical study of PD-1 inhibitor Tislelizumab combined with HMA and cytarabine in the treatment of high-risk myelodysplastic syndromes |
|
|
| Recruiting | N/A | 53 | China | Tislelizumab combined with HMA and cytarabine in the treatment of medium to high-risk myelodysplastic syndromes; enrolled patients received at least two courses of treatment to evaluate the effectiveness and safety. | Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technol ; Union Hospital, Tongji Medical College of HUST, The source of funding for this project is self-raised. | The clinical study of PD-1 inhibitor Tislelizumab combined with HMA and cytarabine in the treatment of high-risk myelodysplastic syndromes | | | | |
ChiCTR2100045297: The clinical study of PD-1 inhibitor Tislelizumab combined with HMA+HA/HAG in the treatment of relapsed and refractory AML and elderly AML |
|
|
| Recruiting | N/A | 69 | China | HMA combined with Tislelizumab plus low-dose chemotherapy for relapsed and refractory AML ;HMA combined with Tislelizumab plus low-dose chemotherapy for the treatment of early-diagnosed AML | Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technol ; Union Hospital, Tongji Medical College of HUST, The source of funding for this project is self-raised. | The clinical study of PD-1 inhibitor Tislelizumab combined with HMA+HA/HAG in the treatment of relapsed and refractory AML and elderly AML | | | | |
NCT06119347: Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors |
|
|
| Completed | N/A | 1581 | RoW | AntiVEGF, ICIs | First Affiliated Hospital of Wenzhou Medical University | AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs | 06/23 | 10/23 | | |
| Recruiting | N/A | 474 | RoW | PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE | Zhongda Hospital | Hepatocellular Carcinoma | 08/23 | 08/23 | | |
CHANCE2202, NCT05332496: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC |
|
|
| Recruiting | N/A | 220 | RoW | PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE | Zhongda Hospital | Hepatocellular Carcinoma | 08/23 | 09/23 | | |
ChiCTR2000039372: Canceled by the investigator. A prospective, single-arm clinical trial of tislelizumab combined gemcitabine and oxaliplatin in the first-line treatment of patients with peripheral T cell lymphoma |
|
|
| Not yet recruiting | N/A | 50 | China | tislelizumab combined with gemcitabine and oxaliplatin | The First Affiliated Hospital of Fujian Medical University ; The First Affiliated Hospital of Fujian Medical University, Beijing Rong He Medical Development Foundation | Peripheral T cell lymphoma | | | | |
ChiCTR2100054954: Tislelizumab combined with recombinant human adenovirus type 5 injection in patients with advanced NSCLC who failed prior immunotherapy: an exploratory single-arm study |
|
|
| Recruiting | N/A | 10 | China | Tislelizumab combined with recombinant human adenovirus type 5 | Nanjing Drum Tower Hospital ; Nanjing Drum Tower Hospital, Beijing Health Promotion Association | non-small cell lung cancer | | | | |
| Recruiting | N/A | 60 | RoW | Treatment Group | Fudan University | Cervical Cancer, Immune Checkpoint Inhibitor, Chemoradiotherapy | 12/23 | 12/24 | | |
ChiCTR2100043195: Phase II Trial of Neoadjuvant Tislelizumab combined with chemotherapy in Muscle-Invasive Bladder Cancer (MIBC) Patients |
|
|
| Recruiting | N/A | 30 | China | tislelizumab with gemcitabine-cisplatin (GC) | Chinese PLA General Hospital ; Chinese PLA General Hospital, Beijing Medical Award Foundation | Bladder urothelial carcinoma | | | | |
ChiCTR2100044773: A phase II clinical study of tislelizumab combined with anlotinib in the treatment of non-squamous NSCLC with EGFR sensitive mutation and failure of previous EGFR TKI therapy |
|
|
| Recruiting | N/A | 30 | China | Tilelizumab combined with Anlotinib | Peking Union Medical College Hospital ; Peking Union Medical College Hospital, Beijing Medical Award Foundation | None small cell lung cancer | | | | |
ChiCTR2100054296: Clinical study of preoperative and postoperative adjuvant tislelizumab in the treatment of recurrent operable head and neck squamous cell carcinoma after radiotherapy |
|
|
| Recruiting | N/A | 30 | China | Tislelizumab combined with cisplatin and paclitaxel | Peking University Stomatological Hospital ; Peking University Stomatological Hospital, Shanghai Lianxiang Public Welfare Foundation | head and neck squamous cell carcinoma | | | | |
| Recruiting | N/A | 300 | RoW | TACE, transarterial chemoembolization, Lenvatinib, levima, Anti-PD-1 monoclonal antibody, PD-1 inhibitor, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, apatinib plus camrelizumab, Apa plus C, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga | Tongji Hospital, Chinese Cooperative Group of Liver Cancer, Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, The Second Affiliated Hospital of Fujian Medical University, Geneplus-Beijing Co. Ltd., Haplox Biotechnology Co., Ltd. | Hepatocellular Carcinoma Non-resectable | 12/23 | 12/24 | | |
| Not yet recruiting | N/A | 78 | RoW | intensity-modulated radiotherapy, IMRT, Pembrolizumab, Keytruda, Sintilimab, Tyvyt, Camrelizumab, AiRuiKa, Tislelizumab, Lenvatinib Mesylate Capsule, LENVIMA | RenJi Hospital | Liver Cancer, Liver Transplant; Complications, Hepatocellular Carcinoma, Portal Vein Thrombosis, Radiotherapy; Complications | 12/23 | 05/24 | | |
ChiCTR2200065840: Efficacy and safety of mitoxantrone hydrochloride liposome injection combined with azacitidine and tislelizumab in the treatment of relapsed/refractory peripheral T-cell lymphoma |
|
|
| Not yet recruiting | N/A | 35 | China | mitoxantrone hydrochloride liposome injection combined with azacitidine and tislelizumab | Tongji Hospital Affiliated to Tongji Medical College Huazhong University of Science and Technology ; Tongji Hospital Affiliated to Tongji Medical College Huazhong University of Science and Technology, CSPC Ouyi Pharmaceutical Co., Ltd. | Relapsed/refractory peripheral T-cell lymphoma | | | | |
NCT06024356: Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer |
|
|
| Not yet recruiting | N/A | 26 | RoW | Thymalfasin | Beijing Friendship Hospital | Colorectal Neoplasms | 12/23 | 03/24 | | |
NCT06154967: To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC) |
|
|
| Not yet recruiting | N/A | 20 | NA | tereotactic body radiotherapy, tislelizumab | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder) | 06/25 | 12/25 | | |
NCT06205732: A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer. |
|
|
| Recruiting | N/A | 100 | RoW | Immunotherapy, targeted therapy. | Qianfoshan Hospital | Carcinoma, Hepatocellular | 12/24 | 12/24 | | |
SALVLIV, NCT06199232: Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment |
|
|
| Recruiting | N/A | 47 | RoW | HAIC+targeted therapy+PD-1 inhibitor, HAIC+Fruquintinib/Cetuximab+Tislelizumab | Peking University | Liver Metastasis Colon Cancer, ctDNA Genotype, MSS, Failed From Standard Treatment | 01/26 | 01/27 | | |
SCHRT, NCT06408584: Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab |
|
|
| Recruiting | N/A | 25 | RoW | | Anhui Provincial Hospital | Esophageal Squamous Cell Carcinoma | 03/27 | 03/27 | | |
NCT06280313: Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension |
|
|
| Recruiting | N/A | 60 | RoW | Splenectomy+Targeted therapy+ Immunotherapy | Zhiyong Huang, Wuhan Union Hospital, China, Wuhan University, Renmin Hospital of Wuhan University, Taihe Hospital, Hubei Cancer Hospital, Xiangyang Central Hospital, Wuhan Central Hospital, Yichang Third Renmin Hospital | Unresectable Hepatocellular Carcinoma | 03/27 | 03/28 | | |
ChiCTR2200058323: Microwave ablation combined with tirelizumab and fuquinitinib in the treatment of third-line and posterior advanced colorectal cancer patients: a single-arm, open, single-center clinical study |
|
|
| Not yet recruiting | N/A | 25 | China | Microwave ablation combined with tirelizumab and fuquintinib | Zhongshan Traditional Chinese Medicine Hospital Affiliated to Guangzhou University of Chinese Medicine ; Zhongshan Traditional Chinese Medicine Hospital Affiliated to Guangzhou University of Chinese Medicine, self-funded | colorectal cancer | | | | |
CCGLC-001, NCT05713994: Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 300 | RoW | HAIC, hepatic arterial infusion chemotherapy of FOLFOX, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Lenvatinib, Lenvima, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga, apatinib plus camrelizumab, Apa plus C, Anti-PD-1 monoclonal antibody, PD-1 inhibitor | Wan-Guang Zhang, Chinese Cooperative Group of Liver Cancer (CCGLC), Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, Haplox Biotechnology Co., Ltd., Geneplus-Beijing Co. Ltd., The Second Affiliated Hospital of Fujian Medical University | Hepatocellular Carcinoma Non-resectable | 04/24 | 12/24 | | |
NCT06448169: Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer |
|
|
| Not yet recruiting | N/A | 200 | NA | PD-1 inhibitor, Tislelizumab | Shandong University, Chinese PLA General Hospital | Triple Negative Breast Cancer, Neoadjuvant Immunotherapy, Sensitivity | 02/26 | 04/26 | | |
ChiCTR2200060484: Application and demonstration of tislelizumab in adjuvant treatment of stage II-IIIA NSCLC |
|
|
| Not yet recruiting | N/A | 50 | China | tislelizumab | Affiliated Hospital of Zunyi Medical University ; Affiliated Hospital of Zunyi Medical University, Affiliated Hospital of Zunyi Medical University | non-small cell lung cancer (NSCLC) | | | | |
NCT06363708: Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer |
|
|
| Not yet recruiting | N/A | 20 | RoW | Tislelizumab, Paclitaxel, Carboplatin | Zhongnan Hospital | Endometrial Neoplasms | 12/25 | 06/26 | | |
ChiCTR2000033416: A prospective, single-arm clinical study on the safety and efficacy of tislelizumab in combination with liposome paclitaxel + cisplatin in the neoadjuvant therapy of potentially resectable local advanced esophageal squamous cell carcinoma |
|
|
| Not yet recruiting | N/A | 30 | China | tislelizumab in combination with liposome paclitaxel+cisplatin | Sixth Medical Center of PLA General Hospital ; Sixth Medical Center of PLA General Hospital, Self-financing | Esophageal squamous cell carcinoma | | | | |
NCT05508399: Biomarker Analysis of Tislelizumab Combined With Chemotherapy for Perioperative Treatment of G/GEJ Adenocarcinoma |
|
|
| Recruiting | N/A | 28 | RoW | DNA panel and RNA Sequencing | Xijing Hospital | Locally Advanced Gastric Adenocarcinoma, PD-1 | 07/24 | 07/26 | | |
NCT05811793: Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma. |
|
|
| Not yet recruiting | N/A | 36 | NA | Tislelizumab and Bevacizumab | Second Affiliated Hospital of Nanchang University, Zhejiang University | Glioblastoma | 12/24 | 12/25 | | |
ChiCTR2100049693: Anlotinib hydrochloride combined with tirelizumab, paclitaxel liposome and nedaplatin in a single-arm, single-center, phase II exploratory clinical study of preoperative neoadjuvant therapy for esophageal squamous cell carcinoma |
|
|
| Not yet recruiting | N/A | 30 | China | Anlotinib capsule combined with tirelizumab, paclitaxel liposome and nedaplatin | The First Affiliated Hospital of Guangxi Medical University ; The First Affiliated Hospital of Guangxi Medical University, BeiGene (Beijing) Biotechnology Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Esophageal cancer | | | | |
ChiCTR2200065916: Safety and efficacy of chemotherapy combined with tirelizumab plus anlotinib in patients with advanced biliary tract cancer |
|
|
| Not yet recruiting | N/A | 20 | China | chemotherapy combined with tirelizumab plus anlotinib | Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine ; Shanghai Jiaotong University School of Medicine, Renji Hospital, Beijing Medical Award Foundation | advanced biliary tract cancer | | | | |
ChiCTR2200067166: A phase II, randomized controlled clinical study based on single-cell sequencing to explore the clinical predictive value of immune cell subsets in the treatment of locally advanced cervical cancer patients with or without tislelizumab combined with concurrent chemoradiotherapy |
|
|
| Not yet recruiting | N/A | 18 | China | tislelizumab + Cisplatin combined with radiotherapy ;Cisplatin combined with radiotherapy | Union Hospital of Tongji Medical College, Huazhong University of Science and Technology ; Union Hopistal Tongji Medical College, Huazhong University of Science and Technology, self-funded | cervical carcinoma | | | | |
ChiCTR2200056354: Neoadjuvant Tislelizumab, followed by surgery and adjuvant chemoradiotherapy in locally advanced oral cavity or oropharynx squamous cell carcinoma: An open-label clinical trial |
|
|
| Recruiting | N/A | 30 | China | Neoadjuvant therapy: Tislelizumab, cisplatin, paclitaxel. Surgery. Adjuvant therapy: RT or cCRT. | Peking University Hospital of Stomatology ; Peking University Hospital of Stomatology, National clinical key discipline construction project | oral cavity or oropharynx carcinoma | | | | |
ChiCTR2200056473: The efficacy and safety of levatinib, folfox4-haic combined with tislelizumab in the treatment of intermediate advanced hepatocellular carcinoma: A singe-center, single-arm, prospective real-world study |
|
|
| Not yet recruiting | N/A | 40 | China | Levatinib, folfox4-haic combined with tislelizumab | The Second Affiliated Hospital of PLA Air Force Military Medical University ; The Second Affiliated Hospital of PLA Air Force Military Medical University, Investigator initiated clinical trials | hepatocellular carcinoma | | | | |
NCT05754203: Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC |
|
|
| Recruiting | N/A | 40 | RoW | Super-hyperfractionation Pulse Radiotherapy, Immune Checkpoint Inhibitor | Xinqiao Hospital of Chongqing | Lung Cancer, Immune Checkpoint Inhibitor, Radiotherapy | 03/25 | 03/25 | | |
NCT06056115: Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic |
|
|
| Recruiting | N/A | 20 | RoW | Tislelizumab,Platinum | Hebei Medical University Fourth Hospital | Lung Adenocarcinoma | 04/25 | 12/26 | | |
NCT05573282: Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 50 | RoW | Regorafenib combine with ICIs | Sun Yat-sen University | Hepatocellular Carcinoma | 06/25 | 01/26 | | |
NCT05546619: Research on Effectiveness and Safety of the Treatment, Hyperthermic Intraperitoneal Chemotherapy Combined With Tislelizumab and Targeted Therapy, That is Used for High-risk Hepatocellular Carcinoma After R0 Resection |
|
|
| Active, not recruiting | N/A | 30 | RoW | HIPEC+tislelizumab + targeted therapy | Sulai Liu | Hepatocellular Carcinoma | 07/25 | 07/25 | | |
ChiCTR2000034748: Tislelizumab combined with chemoradiotherapy in the treatment of recurrent/ metastasis cervical cancer: a single arm,single center， phase II and observational clinical study |
|
|
| Not yet recruiting | N/A | 264 | China | Paclitaxel 135mg / m2d1 + cisplatin 60mg / m2d1 (cisplatin resistance or cisplatin intolerance changed to carboplatin AUC = 5d1), q3w × 4 ;Standard IMRT radiotherapy ;Tislelizumab 200mg, IV, q3w, the day before radiotherapy | Cancer Hospital, Fudan University ; Cancer Hospital, Fudan University, sponsorship | recurrent cervical cancer | | | | |
ChiCTR2200063254: A single arm, multi-center, open lable, exploratory study of Tirelizumab combined with Nab-Paclitaxel and Gemcitabine in the treatment of patients with advanced biliary tract cancer |
|
|
| Not yet recruiting | N/A | 30 | China | Tirelizumab + Nab-Paclitaxel + Gemcitabine | Shanghai Xuhui Central Hospital ; Shanghai Xuhui Central Hospital, BeiGene (Beijing) Co., Ltd.; Qilu Pharmaceutical Co., Ltd. | biliary tract cancer | | | | |
ChiCTR2100053577: A randomized controlled trial of transarterial chemoembolization combined with tislelizumab in neoadjuvant therapy for advanced resectable hepatocellular carcinoma |
|
|
| Recruiting | N/A | 132 | | Surgery after neoadjuvant therapy ;Direct surgery | West China Hospital of Sichuan University; West China Hospital of Sichuan University, Beijing Medical Award Foundation | Hepatocellular carcinoma | | | | |
ChiCTR2200063003: Efficacy and safety of donafenib combined with tislelizumab and TACE for adjuvant therapy in patients with hepatocellular carcinoma after surgery: a single-arm, prospective, exploratory study |
|
|
| Not yet recruiting | N/A | 32 | China | Subjects receive TACE treatment once in the first month after surgery, with tislelizumab 200 mg i.v. q3w (day 1 of each 21-day cycle), and donafenib 200 mg p.o. bid). | West China Hospital of Sichuan University ; West China Hospital of Sichuan University, Horizontal project funded by Suzhou Zejing Biopharmaceutical Co., Ltd. | Hepatocellular Carcinoma | | | | |
ChiCTR2200066635: Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage III NSCLC |
|
|
| Recruiting | N/A | 30 | | Neoadjuvant therapy of Tislelizumab with chemotherapy | Beijing Tsinghua Chang Gung Hospital ; Beijing Tsinghua Chang Gung Hospital, Clinical Research Project of Beijing Tsinghua Chang Gung Hospital | NSCLC | | | | |
NCT05834413: Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors |
|
|
| Not yet recruiting | N/A | 367 | RoW | chemotherapy plus TCM 1&ICIs plusTCM2 placebo, chemotherapy plus TCM 1placebo &ICIs plus TCM2 placebo | Shanghai University of Traditional Chinese Medicine, Shanghai Pulmonary Hospital, Shanghai, China, Shanghai Chest Hospital, Fudan University, Shanghai Zhongshan Hospital, Ruijin Hospital | Lung Cancer | 06/26 | 06/26 | | |
ChiCTR2200062002: A Multicenter Clinical Trial of Neoadjuvant Therapy for Locally Advanced Rectal Cancer Based on Genotyping |
|
|
| Not yet recruiting | N/A | 100 | China | Tislelizumab 200mg ivdrop every 3 weeks for 4 cycles ;mFolfOx6 chemotherapy combined with EGFR monoclonal antibody and Tislelizumab ;Standard neoadjuvant chemoradiotherapy regimen combined with Tislelizumab | Tianjin Medical University General Hospital ; Tianjin Medical University General Hospital, Clinical trial research fund of Tianjin Medical University General Hospital | locally advanced rectal cancer，LARC | | | | |
ChiCTR2200065583: An exploratory, single-arm study of sequential Stereotactic body radiation therapy with tirelizumab for consolidation in early non-small cell lung cancer |
|
|
| Not yet recruiting | N/A | 50 | | SBRT | Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University, Clinical Research Foundation of The Affiliated Hospital of Guangdong Medical University | non-small cell lung cancer | | | | |
ChiCTR2300072094: Tislelizumab combined with recombinant human adenovirus type 5 injection in PD-(L) 1-resistant patients with advanced non-squamous NSCLC |
|
|
| Recruiting | N/A | 20 | China | Tislelizumab combined with recombinant human adenovirus type 5 | Shanxi Provincial Cancer Hospital ; Shanxi Provincial Cancer Hospital, No sponsor | non-small cell lung cancer | | | | |
